103 related articles for article (PubMed ID: 20022305)
21. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis.
Szodoray P; Alex P; Dandapani V; Nakken B; Pesina J; Kim X; Wallis GL; Wilson PC; Jonsson R; Centola M
Scand J Immunol; 2004; 60(1-2):209-18. PubMed ID: 15238091
[TBL] [Abstract][Full Text] [Related]
22. Lower prevalence of circulating invariant natural killer T (iNKT) cells in patients with acute myocardial infarction undergoing primary coronary stenting.
Liu LL; Lu JL; Chao PL; Lin LR; Zhang ZY; Yang TC
Int Immunopharmacol; 2011 Apr; 11(4):480-4. PubMed ID: 21238619
[TBL] [Abstract][Full Text] [Related]
23. Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity.
Lynch L; O'Shea D; Winter DC; Geoghegan J; Doherty DG; O'Farrelly C
Eur J Immunol; 2009 Jul; 39(7):1893-901. PubMed ID: 19585513
[TBL] [Abstract][Full Text] [Related]
24. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
Yukawa N; Mimori T
Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487
[TBL] [Abstract][Full Text] [Related]
25. Frequency of circulating iNKT cells among Iranian healthy adults.
Fereidouni M; Farid Hosseini R; Jabbari Azad F; Schenkel J; Varasteh A; Mahmoudi M
Cytometry B Clin Cytom; 2010 Jan; 78(1):65-9. PubMed ID: 19714727
[TBL] [Abstract][Full Text] [Related]
26. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders.
Thurlings RM; Vos K; Gerlag DM; Tak PP
Arthritis Rheum; 2008 Dec; 58(12):3657-64. PubMed ID: 19035505
[TBL] [Abstract][Full Text] [Related]
27. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response.
Oren S; Mandelboim M; Braun-Moscovici Y; Paran D; Ablin J; Litinsky I; Comaneshter D; Levartovsky D; Mendelson E; Azar R; Wigler I; Balbir-Gurman A; Caspi D; Elkayam O
Ann Rheum Dis; 2008 Jul; 67(7):937-41. PubMed ID: 17981914
[TBL] [Abstract][Full Text] [Related]
28. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
Vos K; Thurlings RM; Wijbrandts CA; van Schaardenburg D; Gerlag DM; Tak PP
Arthritis Rheum; 2007 Mar; 56(3):772-8. PubMed ID: 17328049
[TBL] [Abstract][Full Text] [Related]
29. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
[TBL] [Abstract][Full Text] [Related]
30. Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab.
Palanichamy A; Roll P; Theiss R; Dörner T; Tony HP
Arthritis Rheum; 2008 Dec; 58(12):3665-74. PubMed ID: 19035487
[TBL] [Abstract][Full Text] [Related]
31. Long term treatment of rheumatoid arthritis with rituximab.
Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
[TBL] [Abstract][Full Text] [Related]
32. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M
Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384
[TBL] [Abstract][Full Text] [Related]
33. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients.
Balanescu A; Radu E; Nat R; Regalia T; Bojinca V; Ionescu R; Balanescu S; Savu C; Predeteanu D
Int J Clin Pharmacol Res; 2005; 25(1):9-18. PubMed ID: 15864873
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30.
Gerli R; Lunardi C; Bocci EB; Bobbio-Pallavicini F; Schillaci G; Caporali R; Bistoni O; Pirro M; Pitzalis C; Montecucco C
J Rheumatol; 2008 Jan; 35(1):14-9. PubMed ID: 18061981
[TBL] [Abstract][Full Text] [Related]
36. Induction of complete and sustained remission of rheumatoid pachymeningitis by rituximab.
Schmid L; Müller M; Treumann T; Arnold W; Möller B; Aeberli D; Villiger PM
Arthritis Rheum; 2009 Jun; 60(6):1632-4. PubMed ID: 19479865
[TBL] [Abstract][Full Text] [Related]
37. In active chronic rheumatoid arthritis, dipeptidyl peptidase IV density is increased on monocytes and CD4(+) T lymphocytes.
Ellingsen T; Hornung N; Møller BK; Hjelm-Poulsen J; Stengaard-Pedersen K
Scand J Immunol; 2007 Oct; 66(4):451-7. PubMed ID: 17850590
[TBL] [Abstract][Full Text] [Related]
38. Invariant natural killer T cells in chronic obstructive pulmonary disease.
Chi SY; Ban HJ; Kwon YS; Oh IJ; Kim KS; Kim YI; Kim YC; Lim SC
Respirology; 2012 Apr; 17(3):486-92. PubMed ID: 22098381
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.
De Vita S; Zaja F; Sacco S; De Candia A; Fanin R; Ferraccioli G
Arthritis Rheum; 2002 Aug; 46(8):2029-33. PubMed ID: 12209504
[TBL] [Abstract][Full Text] [Related]
40. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
